Market News How it works Learn FAQ
| RCT 0.132 73.46% | NU 12.36 -18.47% | EWZ 33.885 -20.44% | TGL 0.254 14.67% | SRTM 0.326 -24.24% | BBD 2.855 -29.85% | ITUB 7.6 -21.41% | AZTR 1.615 125.87% | SHFS 0.103 -22.21% | XP 15.575 -48.78% | GCDT 0.1361 -22.71% | CLRO 4.79 47.38% | SOXL 91.64 9.67% | SPCX 149.92 1.65% | NWGL 0.0829 1.10% | PBR 21.94 -16.13% | NVD 3.99 -4.77% | SGRY 23.0703 46.48% | TSLL 10.9599 12.29% | VALE 11.99 -3.31% | RBNE 0.1701 -10.47% | CRWV 57.4626 5.95% | INTC 90.785 4.40% | NVDA 216.2072 2.49% | SOXS 47.41 -9.63% | BITO 10.77 -0.55% | ABEV 2.8 -15.15% | IREN 26.5486 6.60% | JBLU 2.295 -12.57% | NOK 8.625 5.96% | XTND 2.2 24.29% | SPRC 1.5001 37.62% | GPUS 0.1782 5.51% | TQQQ 69.14 4.30% | SBS 4.765 -25.55% | INTR 4.6286 -35.62% | TSLG 5.48 12.53% | RWM 14.435 -0.79% | TSLA 395.443 6.24% | SPDN 8.475 -0.76% | SQQQ 37.975 -4.30% | AAL 12.2055 0.79% | SID 0.9269 -21.45% | GGB 4.765 -6.57% | PBR-A 19.3388 -17.81% | RENT 2.9015 26.15% | LUCD 0.5155 25.43% | CIFR 8.1475 2.61% | KORU 10.9537 3.53% | WULF 12.08 6.71%
TBTheravance Biopharma Inc logo

Theravance Biopharma Inc (TBPH)

NASDAQ · Currency in USD
$17.03 ▲ +0.00 (+0.00%)
As of Sep 23, 4:00 PM ET. Market open.

Summary

Previous Close
$17.03
Open
$17.05
Day's Range
$17.02 – $17.07
52 Week Range
$13.08 – $21.03
Volume
10,016,289
Avg. Volume
635,425
Market Cap
$884.18M
Beta (5Y Monthly)
0.17
PE Ratio (TTM)
16.01
EPS (TTM)
$1.04
Earnings Date
Nov 10, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$17.00

Profile: Theravance Biopharma Inc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
90
CEO
Rick E. Winningham

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution.

Earnings

Next report: Tue, Nov 10, 2026
EPS estimate $0.24 · Revenue est. $21.95M
DateEst.Actual
Aug 10, 2026$0.07-$0.11Miss
May 7, 2026$0.03-$0.10Miss
Mar 19, 2026$0.44$0.06Miss
Nov 10, 2025-$0.12$0.04Beat
Aug 12, 2025-$0.09$1.08Beat
May 8, 2025-$0.21-$0.27Miss

Analyst view

Consensus price target
$17.00 ▼ -0.2%
Range $17.00 – $17.00
Rating: Hold
Buy 24% · Hold 59% · Sell 18%

Similar stocks

Get free alerts on TBPH and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.